Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 4:10:1.
doi: 10.12703/r/10-1. eCollection 2021.

Recent advances in the understanding and management of liposarcoma

Candace L Haddox  1 , Richard F Riedel  1   2
Affiliations
Review

Recent advances in the understanding and management of liposarcoma

Candace L Haddox et al. Fac Rev. .

Abstract

Liposarcomas are a common subfamily of soft tissue sarcoma with several subtypes recognized by the World Health Organization: atypical lipomatous tumors (ALT)/well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid liposarcoma (MLPS), pleomorphic liposarcoma (PLPS), and myxoid pleomorphic liposarcoma (MPLPS). Despite shared adipocytic features among liposarcomas, the clinical approach to each subtype differs based on histology, location, clinical behavior, and specific oncogenic drivers. In this review, we highlight subtype-specific molecular features with the potential to generate novel therapies. We discuss recent clinical trials investigating the use of preoperative radiation therapy for retroperitoneal liposarcoma, chemotherapy, small molecule inhibitors, and innovative immunotherapy approaches and describe how we incorporate these advancements into the management of liposarcoma.

Keywords: Clinical Trials; Dedifferentiated; Immunotherapy; Liposarcoma; Myxoid/Round cell; Pleomorphic; Targeted therapy; Well-differentiated.

PubMed Disclaimer

Conflict of interest statement

Richard F. Riedel has received institutional clinical research support from Aadi, AROG, Blueprint, Daiichi Sankyo, Deciphera, GlaxoSmithKline, Karyopharm, Ignyta, Immune Design, Lilly, NanoCarrier, Novartis, Oncternal, Plexxikon, Roche, Springworks, Threshold, and TRACON. He has served as a consultant or advisor for Bayer, Blueprint, Daiichi Sankyo, Deciphera, Eisai, EMD Serono, Janssen, Lilly, Loxo, NanoCarrier, and Springworks. Candace L. Haddox declares that she has no competing interests.No competing interests were disclosed.No competing interests were disclosed.

References

    1. WHO Classification of Tumours Editorial Board: WHO Classification of Tumours of Soft Tissue and Bone. 5th ed. Lyon, France: IARC Press; 2020. Reference Source
    1. Toro JR, Travis LB, Wu HJ, et al. : Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer. 2006; 119(12): 2922–30. 10.1002/ijc.22239 - DOI - PubMed
    1. Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. : World Health Organization Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon, France: IARC Press; 2013. Reference Source
    1. Haddox CL, Riedel RF: Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology. Expert Rev Anticancer Ther. 2020; 20(1): 5–8. 10.1080/14737140.2020.1708198 - DOI - PubMed
    1. Thway K: Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review. Semin Diagn Pathol. 2019; 36(2): 112–21. 10.1053/j.semdp.2019.02.006 - DOI - PubMed

    2. Faculty Opinions Recommendation

LinkOut - more resources